patehan
23 Mar 2016
Question ?? I've been with this stock since 66p.A broker this week stated a buy with a target of 120p.So why has it take a dip of 08p?Anyone know? Please advise.I'm a holder for a very long term...Thanks in advance
II Editor
22 Mar 2016
NEW ARTICLE: Stockwatch: New highs predicted for this share "Can LSE:CLL:Cello break out of an approximate 80-100p range it has traded for the last two years? The five-year chart context for this AIM-listed pharmaceutical and consumer strategic marketing stock shows a strong advance from 38p in 2013, ..."[link]
Welsheagle
27 Jan 2016
Positive trading update CELLO GROUP27 Jan 2016 07
06Cello Group plc RNS Number : 0727NCello Group plc27 January 2016 FOR IMMEDIATE RELEASE 27 JANUARY 2016 Cello Group plc('Cello' or the 'Group')PRE CLOSE TRADING STATEMENTCello, the health and consumer strategic marketing group, today publishes the following update for the year ended 31 December 2015.The Group has experienced good trading for the year, with revenues and headline profits in line with consensus market expectations.Highlights- Cello Health maintains good like-for-like revenue growth and a competitive profit margin- Cello Signal also delivers good like-for-like revenue growth, with an improving profit margin- Cello Signal benefits from aligning its core activities behind the client-facing Signal brand- The Group ends the year with net debt below £5.0m- Strong bookings momentum from Q4 2015 provides good visibility for the start of 2016Cello HealthIn 2015 Cello Health continued to benefit from trading as a unified business under its global client-facing brand, delivering good like-for-like revenue growth, and maintaining a competitive operating profit margin. The US continued to increase its share of overall revenue and profit generation, underpinned by the ongoing development of new offices in San Francisco and Chicago.Cello Health Insight, Cello Health Consulting and Cello Health Communications maintained strong like-for-like revenue growth, at a very competitive overall operating profit margin. Cello Health Consumer had a slower year, with a decline in revenues and profits due to certain project deferrals.Good progress was made in developing the new biotech client base, to complement the core pharmaceutical revenue base of the business, on the West Coast of the US with key client wins during the year. The new start-up office in Boston required a larger investment cost than originally anticipated resulting in a larger start-up loss for the year. Overall growth prospects for Cello Health in the US biotech area are strong as this sector continues to develop.Cello SignalIn 2015 Cello Signal began to see the benefits of trading as a unified business under its core client-facing Signal brand, securing a number of large multi-disciplinary contracts with major brands, including The Royal Bank of Scotland. As a result, the business delivered a strong second half of the year, with good full year like-for-like revenue growth and an improving operating profit margin.The new office network in the US which has grown revenues strongly, achieved a break-even position and should now come into profit in 2016, albeit at a lower margin for a period. Pulsar, Signal's social media software analytics product, almost doubled sales from software licence sales in the period to over £2.0m and reduced its headline loss position materially. This again should come into profit for 2016. As part of the strategic migration of digital skills into Cello Health, the Group will shortly launch a Pulsar supported social media analytics application for pharmaceutical and healthcare clients.Signal is committed to the progressive raising of its operating profit margin. One consequence of this is an exceptional charge of c. £0.7m reflecting action taken to reduce costs during the year.Balance sheetNet debt at year end was less than £5.0m, reflecting solid cash flow conversion for the period.Negotiations are ongoing with HMRC regarding potential VAT on work for UK charities. The Group and its advisers continue to believe that its current provision for VAT and associated expenses of £3.2m is appropriate. Whilst progress has been made with HMRC on this issue, it has as yet not been concluded. The provision made is before any client re
patehan
22 Jan 2016
What's happening? Anyone have any idea as to what is happening with Cello. I understand that there negativity regarding China. However, what lies ahead for Cello? Hold, Buy, or Sell????
Lupo di mare
16 Sep 2015
Interims Not quite what I expected, and not much improvement expected by the year end. I missed the chance to sell first thing, so I'm holding.Unless they're guilty of talking up the prospects, not unknown, it's probably fairly rated with the prospects of pulsar to add a bit of flavour.
Lupo di mare
30 Jul 2015
Chime Hullo, I see that Chime's had an offer. Wonder if that'll lift Cello. I know, not directly comparable.
forwardloop
27 Jul 2015
info [link]
forwardloop
21 Jul 2015
info [link]
Lupo di mare
21 Jul 2015
Update Still expecting current full year expectations to be met.All in all, a reasonable update, IMO. Signal first half slow down was, as they say, signalled in the AGM statement, but second half expected to show improvement, and year as a whole. Boston benefiting from increased headcount, and West Coast bent on doing same. Acquisitions being actively pursued.On 2015 p/e of abt 11.5, a yield of nearly 3%, a PEG of abt 2, and with growth expected, I'm holding.
Lupo di mare
15 Jun 2015
Re: IC Tip That explains the recent rise. They're a tad late at the party.
nk1999
11 Jun 2015
IC Tip "Healthcare and technology marketing group Cello (CLL) is supplementing solid organic growth with acquisitions while expanding into US healthcare, biotech and other exciting niche markets. Yet its shares trade at just 11 times forecast earnings for 2015, dropping to 10 times in 2016, and come with a tidy prospective yield...........IC VIEW:Cello's blue-chip client base, overseas expansion, niche-market focus and acquisitions should support growth for years to come. That doesn't look adequately reflected by the shares' lowly rating. Buy.Last IC view: Buy, 94p, 18 September 2014"
II Editor
07 Apr 2015
NEW ARTICLE: Stockwatch: A sound tuck-away for your ISA "What next for LSE:CLL:Cello? After trading sideways since early 2014Â and with a VAT inquiry hanging over, it's easy to pass by this AIM-listed marketing services stock. With the help of small takeovers however the group has achieved strong ..."[link]
